Empagliflozin in children with glycogen storage disease-associated inflammatory bowel disease: a prospective, single-arm, open-label clinical trial
Abstract Glycogen storage disease type Ib (GSD-Ib) is a rare inborn error of glycogen metabolism caused by mutations in SLC37A4. Patients with GSD-Ib are at high risk of developing inflammatory bowel disease (IBD). We evaluated the efficacy of empagliflozin, a renal sodium‒glucose cotransporter prot...
Main Authors: | Zhiling Li, Xiaoyan Zhang, Huan Chen, Hanshi Zeng, Jiaxing Wu, Ying Wang, Ni Ma, Jiaoli Lan, Yuxin Zhang, Huilin Niu, Lei Shang, Xun Jiang, Min Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2024-04-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-024-59320-z |
Similar Items
-
Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib
by: Sarah C. Grünert, et al.
Published: (2020-08-01) -
Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients
by: Zufit Hexner-Erlichman, et al.
Published: (2022-11-01) -
Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
by: Arianna Maiorana, et al.
Published: (2023-04-01) -
The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience
by: Joanna Bidiuk, et al.
Published: (2022-06-01) -
Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study
by: Sarah C. Grünert, et al.
Published: (2023-05-01)